Literature DB >> 20598711

Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients.

Ilja Spellmann1, Dan Rujescu, Richard Musil, Andreas Mayr, Ina Giegling, Just Genius, Peter Zill, Sandra Dehning, Markus Opgen-Rhein, Anja Cerovecki, Annette M Hartmann, Martin Schäfer, Brigitta Bondy, Norbert Müller, Hans-Jürgen Möller, Michael Riedel.   

Abstract

The HOMER 1 protein plays a crucial role in mediating glutamatergic neurotransmission. It has previously shown to be a candidate gene for etiology and pathophysiology of different psychiatric diseases such as schizophrenia. To identify genes involved in response to antipsychotics, subgroups of animals were treated with haloperidol (1 mg/kg, n = 11) or saline (n = 12) for one week. By analyzing microarray data, we replicated the observed increase of Homer 1 gene expression. Furthermore, we genotyped 267 schizophrenic patients, who were treated monotherapeutically with different antipsychotics within randomized-controlled trials. Psychopathology was measured weekly using the PANSS for a minimum of four and a maximum of twelve weeks. Correlations between PANSS subscale scores at baseline and PANSS improvement scores after four weeks of treatment and genotypes were calculated by using a linear model for all investigated SNP's. We found an association between two HOMER 1 polymorphisms (rs2290639 and rs4704560) and different PANSS subscales at baseline. Furthermore all seven investigated polymorphisms were found to be associated with therapy response in terms of a significant correlation with different PANSS improvement subscores after four weeks of antipsychotic treatment. Most significant associations have been shown between the rs2290639 HOMER 1 polymorphism and PANSS subscales both at baseline conditions and after four weeks of antipsychotic treatment. This is the first study which shows an association between HOMER 1 polymorphisms and psychopathology data at baseline and therapy response in a clinical sample of schizophrenic patients. Thus, these data might further help in detecting differential therapy response in individuals with schizophrenia. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20598711     DOI: 10.1016/j.jpsychires.2010.06.004

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  23 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

Review 2.  Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.

Authors:  Andrea de Bartolomeis; Gianmarco Latte; Carmine Tomasetti; Felice Iasevoli
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

Review 3.  Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins.

Authors:  Ana C Magalhaes; Henry Dunn; Stephen Sg Ferguson
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 4.  Regulation and Function of Activity-Dependent Homer in Synaptic Plasticity.

Authors:  Nicholas E Clifton; Simon Trent; Kerrie L Thomas; Jeremy Hall
Journal:  Mol Neuropsychiatry       Date:  2019-05-23

5.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-05-28       Impact factor: 6.186

Review 6.  Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases.

Authors:  Felice Iasevoli; Carmine Tomasetti; Andrea de Bartolomeis
Journal:  Neurochem Res       Date:  2012-09-19       Impact factor: 3.996

7.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-07       Impact factor: 6.186

8.  The pharmacogenetics of symptom response to antipsychotic drugs.

Authors:  Gavin P Reynolds
Journal:  Psychiatry Investig       Date:  2012-01-09       Impact factor: 2.505

9.  Homer1a protein expression in schizophrenia, bipolar disorder, and major depression.

Authors:  Stefan L Leber; Ida C Llenos; Christine L Miller; Jeannette R Dulay; Johannes Haybaeck; Serge Weis
Journal:  J Neural Transm (Vienna)       Date:  2017-08-16       Impact factor: 3.575

10.  Association study of early-immediate genes in childhood-onset mood disorders and suicide attempt.

Authors:  John Strauss; Stuart McGregor; Natalie Freeman; Arun Tiwari; Charles J George; Maria Kovacs; James L Kennedy
Journal:  Psychiatry Res       Date:  2012-03-27       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.